Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review
| Autor: | K. Umezawa, Sh. Kh. Gantsev, Sh. R. Kzyrgalin, R. S. Yamidanov, R. A. Amirov, E. I. Zhuk |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Креативная хирургия и онкология, Vol 11, Iss 1, Pp 68-75 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2307-0501 2076-3093 |
| DOI: | 10.24060/2076-3093-2021-11-1-68-75 |
| Popis: | Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-κB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-κB-mediated pathways’ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-κB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|